1. Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis
- Author
-
Pizga Kumwenda, Elton Chavura, Saul Eric Mwale, Master Chisale, Atipatsa Chiwanda Kaminga, Billy Nyambalo, Mep Chipeta, Sheena Ramazanu, Balwani Chingatichifwe Mbakaya, and Obed Nkhata
- Subjects
Male ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Review ,CINAHL ,Antibodies, Viral ,Africa, Southern ,SARS‐CoV‐2 ,Herd immunity ,Seroepidemiologic Studies ,antibody ,Virology ,Humans ,Medicine ,Seroprevalence ,Aged ,Covid‐19 ,seroprevalence ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Middle Aged ,Critical appraisal ,Infectious Diseases ,Meta-analysis ,Africa ,biology.protein ,Antibody ,business ,Demography - Abstract
We estimated the seroprevalence of anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre‐prints that reported anti‐SARS‐CoV‐2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were evaluated using Joana Briggs Institute prevalence critical appraisal tool. Twenty‐three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa was 22% (95%CI: 14–31) with very high heterogeneity (I 2 = 100%, p
- Published
- 2021
- Full Text
- View/download PDF